

GENENT.065A



RECEIVED

AUG 09 2001

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : De Sauvage et al.

Appl. No. : 09/272,835

Filed : March 19, 1999

For : GFRALPHA3 AND ITS USES

Examiner : R. Hayes

) Group Art Unit 1647

) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as first-class
) mail in an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

August 2, 2001

(Date)

Ginger R. Dreger, Reg. No. 33,055

16/c
H.G.J
8/10/01

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In reponse to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on July 10, 2001 (Paper No. 15), setting a one month term, Applicants hereby request the entry of the substitute "Sequence Listing" submitted concurrently herewith into the specification, starting on a new page, immediately following the claims, and of the following amendments to the specification.

In the Specification:

Please replace the paragraph beginning at page 7, line 35, with the following rewritten paragraph:

C! Figure 5A-B shows the nucleic acid sequence alignment of the DNA sequence (SEQ ID NO: 14) encoding human GFR α 3 with DNAs encoding human GFR α 1 (SEQ ID NO: 6) and human GFR α 2 (SEQ ID NO: 7), respectively.